source
- Rezera targets $181 million IPO to fund phase-3 trial of NLRP3 inhibitor for peripheral artery diseaseBoston-based biotech Rezera, which rebranded from NodThera last September, said it will seek an initial public offering to raise about $181 million. The proceeds are intended to move its brain-pene…
- Alethio Therapeutics raises $90 million Series A to develop antibody for essential thrombocythemiaAlethio Therapeutics, a spinout from the University of Oxford, announced a $90 million Series A financing round. The capital will fund the company’s lead program, an antibody designed to treat ess…